PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Adding Liriope Tuber to conventional medicine reduced PAF frequency, left atrium diameter, and P-wave dispersion [PMID:39247398]
Shashen-Maidong decoction combined with Western medicine was evaluated for efficacy and safety in a retrospective cohort [PMID:38045652]
Liriope muscari extract significantly reduced biofilm formation by 51.65% at 1.56 ug/mL and inhibited dimorphic transition [PMID:38786162]
Maidong polysaccharide extract increased insulin secretion and reduced blood glucose in db/db mice [PMID:32605924]
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 36058477 (2022) — Shashen-Maidong Decoction inhibited cancer growth under intermittent hypoxia conditions by suppressing oxidative stress and inflammation. · Journal of ethnopharmacology
- 2.PMID: 39419302 (2025) — Mechanism of Shashen-Maidong herb pair in treating hepatocellular carcinoma using network pharmacology and experimental validation. · Journal of ethnopharmacology
- 3.PMID: 36291700 (2022) — Quality Evaluation of Ophiopogon japonicus from Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides. · Biomolecules
- 4.PMID: 38786162 (2024) — Inhibition of Candida albicans Biofilm Formation and Attenuation of Its Virulence by Liriope muscari. · Antibiotics (Basel, Switzerland)
- 5.PMID: 39524804